|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
These include B-lymphocyte proliferation and sustained clonal expansion by HCV-envelope protein stimulation of B-cell receptors, and prolonged HCV-infected B-cell growth by overexpression of an anti-apoptotic BCL-2 oncogene caused by the increased frequency of t(14;18) chromosomal translocations in follicular lymphomas.
|
31092372 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, either DLBCL or FL can give rise to aggressive double-hit lymphomas (DHL) with concurrent activation of MYC and BCL2.
|
30874346 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We showed that DLBCL with MYC/BCL2-DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation.
|
31844144 |
2019 |
|
Lymphoma, Follicular
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we tested its ability to discriminate follicular lymphomas by the tumour grade and the BCL2 protein expression.
|
30609603 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL) with genetic alterations of BCL-2, KMT2B, and KMT6.
|
30693983 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL.
|
30850381 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MiR-429 was upregulated and SOX2 and BCL2 were downregulated in the AD mouse model and Aβ-induced mouse cortical neurons.
|
30264333 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Therapeutic
|
disease |
RGD |
Bajijiasu Ameliorates β-Amyloid-Triggered Endoplasmic Reticulum Stress and Related Pathologies in an Alzheimer's Disease Model.
|
29587274 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Melatonin significantly ameliorated the cognitive function and mitochondrial damage in AD mice, reduced the expression levels of GSK-3β, caspase-3, Aβ<sub>1-42</sub> , BACE1, p-tau protein and increased the expressions of PP2A and Bcl-2.
|
28994117 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
CP alterations in iron contents were mediated through DMT1(-IRE) and changes in ROS levels, which in turn attenuated the progression of AD through the Erk/p38 and Bcl-2/Bax signaling pathways.
|
28874056 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Therapeutic
|
disease |
RGD |
CART peptide activates the Nrf2/HO-1 antioxidant pathway and protects hippocampal neurons in a rat model of Alzheimer's disease.
|
29777699 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We stratified 75 brain tissues from Alzheimer's disease into hyperphosphorylated tau positive or negative and did co-expression analyses and qRTPCR for importin-β and exportin-5 plus several bcl2 family members and compared the data to controls, Down's dementia and Parkinson's disease.
|
29414391 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Afterwards, several hub genes such as INSR, VEGFA, PRKACB, DLG4, and BCL2 that might play key roles in Mn-induced AD were further screened out.
|
29851783 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We present an overview of how a) NPD1 selectively mediates preconditioning rescue of RPE and PR cells; b) NPD1 restores aberrant neuronal networks in experimental epileptogenesis; c) the decreased ability to biosynthesize NPD1 in memory hippocampal areas of early stages of Alzheimer's disease takes place; d) NPD1 protection of dopaminergic circuits in an in vitro model using neurotoxins; and e) bioactivity elicited by DHA and NPD1 activate a neuroprotective gene-expression program that includes the expression of Bcl-2 family members affected by Aβ42, DHA, or NPD1.
|
30244005 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of B cell lymphoma 2 (Bcl‑2) were increased, and the expression levels of caspase‑3, Bcl‑2 associated X protein and AD‑associated proteins were decreased in the hippocampus following treatment with vildagliptin.
|
29257340 |
2018 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the Bcl-2 rs956572 polymorphism is associated with different strengths of structural covariance in AD that determine clinical outcomes.
|
29422088 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The pro-apoptotic Bcl-2 homology 3 domain only (BH3-only) proteins are central regulators of cell death in various physiological and pathological conditions, including Alzheimer's disease (AD).
|
29499358 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have demonstrated the therapeutic potential of miR-15a in colon cancer. miR-15a inhibits several important genes (<i>BCL2, BMI1, YAP1</i> and <i>DCLK1</i>), decreasing cancer progression and resistance.
|
29416778 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study aimed to explore the role of B-cell lymphoma 2 (BCL-2) in promoting colon cancer development associated with LIN28B.
|
29669301 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting Bcl-2 proteins via DZNep or BH3 mimetics could increase the therapeutic potential of MDM2-antagonists like Nutlin-3a in colon cancer.
|
29394130 |
2018 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expressions of C-MYC and BCL-2 in colon cancer tissues exhibited high levels of expression, while miR-184 displayed relatively low levels in comparison to the adjacent normal tissues.
|
28782841 |
2018 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
This investigation was conducted to construct a hypoxia/colorectal dual-specific bidirectional short hairpin RNA (shRNA) expression vector and to transfect it into the colon cancer cell line HT-29 with PEI/chitosan-TBA nanoparticles for the simultaneous knock down of β-catenin and Bcl-2 under hypoxia.
|
29656061 |
2018 |
|
Lymphoma, Follicular
|
0.600 |
Biomarker
|
disease |
BEFREE |
Molecular cytogenetics showed IGH/BCL2 fusion in the follicular lymphoma and amplification of IGH gene or trisomy/tetrasomy 14 in the PTCL.
|
29217426 |
2018 |
|
Lymphoma, Follicular
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Follicular lymphoma (FL) is the most frequent indolent lymphoma in the Western world and is characterized in almost all cases by the t(14;18) translocation that results in overexpression of BCL2, an anti-apoptotic protein.
|
29974035 |
2018 |